Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations
Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization application is specific for men whose disease progressed after treatment that included a newer hormone therapy, such as Xtandi (enzalutamide) or Zytiga (abiraterone acetate). The positive opinion by the Committee for Medicinal Products for Human Use (CHMP) was based on a subgroup analysis of mCRPC patients with BRCA mutations from the Phase 3 
Subscribe or to access all post and page content.